Author

E. Heylen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Organism:rat· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

V. Vergote· 4 shared B. Weynand· 3 shared D. Jochmans· 3 shared J. Neyts· 3 shared J. Rocha-Pereira· 3 shared K. Dallmeier· 3 shared L. Coelmont· 3 shared L. Delang· 3 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

V. Vergote

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

C. S. Foo, R. Abdelnabi, S. J. F. Kaptein, X. Zhang, S. ter Horst, R. Mols, L. Delang, J. Rocha-Pereira, L. Coelmont, P. Leyssen, K. Dallmeier, V. Vergote, E. Heylen, L. Vangeel, A. K. Chatterjee, , J. Neyts

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

bioRxiv · Feb 1, 2021 · PreprintMicrobiology

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

R. Abdelnabi, C. S. Foo, S. J. F. Kaptein, X. Zhang, L. Langendries, L. Vangeel, J. Breuer, J. Pang, R. Williams, V. Vergote, E. Heylen, P. Leyssen, K. Dallmeier, L. Coelmont, D. Jochmans, , J. Neyts

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

bioRxiv · Dec 10, 2020Microbiology

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

S. J. Kaptein, S. Jacobs, L. Langendries, L. Seldeslachts, S. ter Horst, L. Liesenborghs, B. Hens, V. Vergote, E. Heylen, E. Maas, C. De Keyzer, L. Bervoets, J. Rymenants, T. Van Buyten, H. J. Thibaut, , L. Delang

This study evaluates the antiviral effects of favipiravir and hydroxychloroquine in SARS-CoV-2-infected hamsters, finding limited efficacy for both drugs.

bioRxiv · Jun 19, 2020 · PreprintMicrobiology

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters

R. Boudewijns, H. J. Thibaut, S. J. F. Kaptein, R. Li, V. Vergote, L. Seldeslachts, C. De Keyzer, L. Bervoets, S. Sharma, J. Van Weyenbergh, L. Liesenborghs, J. Ma, S. Jansen, D. Van Looveren, T. Vercruysse, , X. Saelens

This study shows that STAT2 signaling both restricts SARS-CoV-2 spread and causes severe pneumonia in infected hamsters.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology